TERESA MACARULLA


Current positions

  • Teresa Macarulla was Attending Physician at Gastrointestinal Tumors Service of the Medical Oncology Service at the University Hospital of Vall d’Hebron from 2004 to 2016. She is currently Principal Investigator of VHIO´s Gastrointestinal and Endocrine Tumors Group, headed by Josep Tabernero, Director of VHIO.

Academic Qualifications

  • Teresa Macarulla received her medical degree from the Universitat Autònoma de Barcelona, Spain, and carried out her residency at the Department of Medical Oncology at the University Hospital Sant Pau, Universitat Autònoma de Barcelona, and obtained her PhD Degree in Medicine and Surgery at the Universitat Autonoma de Barcelona with “Cum Laude“ in 2015.

Areas of Research

  • She is co-investigator of several studies aimed at developing novel molecules against cancer, especially in the field of EGFR inhibition (recipient of the factor of epidermal growth), mutations or hyperactivity of which have been associated with the development of cancer. She is specialized in new targeted therapies against GI tumours, especially colon, hepatocarcinoma, pancreatic and biliary tract cancers. In addition, she assumes a key role within the Medical Oncology Department of the Vall d’Hebron University Hospital (HUVH).
  • Clinical research: As attending Physician of HUVH´s Medical Oncology Department and PI of VHIO´s Gastrointestinal & Endocrine Tumors Group, one of her principal undertakings surrounds clinical research and studies. In gastrointestinal tumors patients are included in clinical trials (phase I, II or III) specifically dedicated to ultimately improving outcomes for individuals with malignant colon, gastric, hepatocarcinoma, pancreatic, biliary, and oesophageal cancers. She has taken part and contributed in the design of clinical studies either as Principal Investigator or as part of trials developed within the context of cooperative national and international groups, as well as those supported by pharmaceutical companies.
  • Pre-clinical research: She is committed to the development of new therapies and phase I studies in solid tumours. Her particular interests focus on the development of therapies of molecular reveilles with a special emphasis on defining biological ideal dose through the analysis of pharmacokinetics/pharmacodynamics. Simultaneously she has also contributed to the characterization of molecular biomarkers of clinical efficiency in phase I trials.
  • Molecular scoreboards in gastrointestinal tumours: Teresa Macarulla is also dedicated to advancing insights into predictive factors of response and efficacy across various gastrointestinal tumors.

Prizes and Scholarships

  • Nanomedicine Upscaling for Early Clinical Phases of Multimodal Cancer Therapy (NoCanTher). H2020 Framework Programme. Principal Investigator.
  • FP7-HEALTH-2013-602901 (MERCURIC): Phase I study of MEK1/2 inhibitor PD-0325901 with cMET inhibitor PF-02341066 in KRASMT and KRASWT (with aberrant c-MET) Colorectal Cancer Patients. Co-Investigator. 2013-2020.
  • RD12/0036/0012. CARLOS III HEALTH INSTITUTE. Cancer Cooperative Research Thematic Network (RTICC). Co-Investigator. 2013-2016.
  • Collaborative research of Anti-Epiregulin (EREG) Antibody project for promotion of personalized healthcare (PHD). CHUGAI PHARMACEUTICAL CO. LTD. Co-Investigator. 2013-2014.
  • PI11/00917. CARLOS III HEALTH INSTITUTE: Identification of predictive biomarkers of response and resistance to biological treatment and identification of subtypes in metastatic colorectal cancer (mCRC). Co-Investigator. 2015-2017.
  • European Commission Horizon 2020. ref.635342. Molecularly guided trials with specific treatment strategies in patients with advanced newly molecular defined subtypes of colorectal cancer (MoTriColor). Co-Investigator. 2015-2018.
  • Development of a systems biology method to predict efficacy of cancer drugs to optimize individualized therapeutics decision and improve clinical outcome for cancer patients (WINTHER). Seventh Framework Program. Co-Investigator

Most relevant scientific publications

  • De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, Fountzilas G, Kalogeras KT, Kotoula V, Papamichael D, Laurent-Puig P, Penault-Llorca F, Rougier P, Vincenzi B, Santini D, Tonini G, Cappuzzo F, Frattini M, Molinari F, Saletti P, De Dosso S, Martini M, Bardelli A, Siena S, Sartore-Bianchi A, Tabernero J, Macarulla T, Di Fiore F, Gangloff AO, Ciardiello F, Pfeiffer P, Qvortrup C, Hansen TP, Van Cutsem E, Piessevaux H, Lambrechts D, Delorenzi M, Tejpar S. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol. 2010 Aug; 11(8):753-62.
  • Wolpin BM, O’Reilly EM, Ko YJ, Blaszkowsky LS, Rarick M, Rocha-Lima CM, Ritch P, Chan E, Spratlin J, Macarulla T, McWhirter E, Pezet D, Lichinitser M, Roman L, Hartford A, Morrison K, Jackson L, Vincent M, Reyno L, Hidalgo M. Global, multicenter, randomized, phase II trial of gemcitabine and gemcitabine plus AGS-1C4D4 in patients with previously untreated, metastatic pancreatic cancer. Ann Oncol. 2013 Jul; 24(7):1792-801
  • Heinemann V, Reni M, Ychou M, Richel DJ, Macarulla T, Ducreux M. Tumour-stroma interactions in pancreatic ductal adenocarcinoma: rationale and current evidence for new therapeutic strategies. Cancer Treat Rev. 2014 Feb; 40(1):118-28.
  • Roepman P, Schlicker A, Tabernero J, Majewski I, Tian S, Moreno V, Snel MH, Chresta CM, Rosenberg R, Nitsche U, Macarulla T, Capella G, Salazar R, Orphanides G, Wessels LF, Bernards R, Simon IM. Colorectal cancer intrinsic subtypes predict chemotherapy benefit, deficient mismatch repair and epithelial-to-mesenchymal transition. Int J Cancer. 2014 Feb 1; 134(3):552-62.
  • Elez ME, Tabernero J, Geary D, Macarulla T, Kang SP, Kahatt C, Pita AS, Teruel CF, Siguero M, Cullell-Young M, Szyldergemajn S, Ratain MJ. First-in-human phase I study of Lurbinectedin (PM01183) in patients with advanced solid tumors. Clin Cancer Res. 2014 Apr 15; 20(8):2205-14.
  • Geva R, Vecchione L, Kalogeras KT, Vittrup Jensen B, Lenz HJ, Yoshino T, Paez D, Montagut C, Souglakos J, Cappuzzo F, Cervantes A, Frattini M, Fountzilas G, Johansen JS, Høgdall EV, Zhang W, Yang D, Yamazaki K, Nishina T, Papamichael D, Vincenzi B, Macarulla T, Loupakis F, De Schutter J, Spindler KL, Pfeiffer P, Ciardiello F, Piessevaux H, Tejpar S. FCGR polymorphisms and cetuximab efficacy in chemorefractory metastatic colorectal cancer: an international consortium study. Gut. 2014 Jul 10. pii: gutjnl-2014-307234.
  • Macarulla T, Sauri T, Tabernero J. Evaluation of aflibercept in the treatment of metastatic colorectal cancer. Expert Opin Biol Ther. 2014 Oct; 14(10):1493-505.
  • Bonnetain F, Bonsing B, Conroy T, Dousseau A, Glimelius B, Haustermans K, Lacaine F, Van Laethem JL, Aparicio T, Aust D, Bassi C, Berger V, Chamorey E, Chibaudel B, Dahan L, De Gramont A, Delpero JR, Dervenis C, Ducreux M, Gal J, Gerber E, Ghaneh P, Hammel P, Hendlisz A, Jooste V, Labianca R, Latouche A, Lutz M, Macarulla T, Malka D, Mauer M, Mitry E, Neoptolemos J, Pessaux P, Sauvanet A, Tabernero J, Taieb J, van Tienhoven G, Gourgou-Bourgade S, Bellera C, Mathoulin-Pélissier S, Collette L. Guidelines for time-to-event end-point definitions in trials for pancreatic cancer. Results of the DATECAN initiative (Definition for the Assessment of Time-to-event End-points in Cancer trials. Eur J Cancer. 2014 Nov; 50(17):2983-93
  • Katsila T, Juliachs M, Gregori J, Macarulla T, Villarreal L, Bardelli A, Torrance C, Elez E, Tabernero J, Villanueva J. Circulating pEGFR is a candidate response biomarker of cetuximab therapy in colorectal cancer. Clin. Cancer Res. 2014 Dec 15; 20(24):6346-56.
  • Ruff P, Ferry DR, Lakomỳ R, Prausová J, Van Hazel GA, Hoff PM, Cunningham D, Arnold D, Schmoll HJ, Moiseyenko VM, McKendrick JJ, Ten Tije AJ, Vishwanath RL, Bhargava P, Chevalier S, Macarulla T, Van Cutsem E. Time course of safety and efficacy of aflibercept in combination with FOLFIRI in patients with metastatic colorectal cancer who progressed on previous oxaliplatin-based therapy. Eur J Cancer. 2015 Jan; 51(1):18-26
  • Sanz-Garcia E, Saurí T, Tabernero J, Macarulla T.Pharmacokinetic and pharmacodynamic evaluation of aflibercept for the treatment of colorectal cancer. Expert Opin Drug Metab Toxicol. 2015 Jun; 11(6):995-1004. Doi: 10.1517/17425255.2015.1041920. Review.
  • Macarulla T, Cervantes A, Tabernero J, Roselló S, Van Cutsem E, Tejpar S, Prenen H, Martinelli E, Troiani T, Laffranchi B, Jego V, von Richter O, Ciardiello F.Phase I study of FOLFIRI plus pimasertib as second-line treatment for KRAS-mutated metastatic colorectal cancer.Br J Cancer. 2015 Jun 9; 112(12):1874-81. Doi: 10.1038/bjc.2015.144. Epub 2015 May
  • Carrato A, García P, López R, Macarulla T, Rivera F, Sastre J, Gostkorzewicz J, Benedit P, Pérez-Alcántara F.Cost-utility analysis of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) in combination with gemcitabine in metastatic pancreatic cancer in Spain: results of the PANCOSTABRAX study. Expert Rev Pharmacoecon Outcomes Res. 2015; 15(4):579-89. Doi: 10.1586/14737167.2015.1047349. Epub 2015 May 19.
  • Benavides M, Antón A, Gallego J, Gómez MA, Jiménez-Gordo A, La Casta A, Laquente B, Macarulla T, Rodríguez-Mowbray JR, Maurel J.Biliary tract cancers: SEOM clinical guidelines. ClinTransl Oncol. 2015 Dec; 17(12):982-7. Doi: 10.1007/s12904 – 015-1436-2. Epub 2015 Nov 25.
  • Van Cutsem E, Joulain F, Hoff PM, Mitchell E, Ruff P, Lakomý R, Prausová J, Moiseyenko VM, van Hazel G, Cunningham D, Arnold D, Schmoll HJ, Ten Tije AJ, McKendrick J, Kröning H, Humblet Y, Grávalos C, Le-Guennec S, Andria M, Dochy E, Vishwanath RL, Macarulla T, Tabernero J. Aflibercept Plus FOLFIRI vs. Placebo Plus FOLFIRI in Second-Line Metastatic Colorectal Cancer: a Post Hoc Analysis of Survival from the Phase III VELOUR Study Subsequent to Exclusion of Patients who had Recurrence During or Within 6 Months of Completing Adjuvant Oxaliplatin-Based Therapy. Target Oncol. 2015 Dec 26. [Epub ahead of print).
  • Goldstein D, Von Hoff DD, Moore M, Greeno E, Tortora G, Ramanathan RK, Macarulla T, Liu H, Pilot R, Ferrara S, Lu B. Development of peripheral neuropathy and its association with survival during treatment with nab-paclitaxel plus gemcitabine for patients with metastatic adenocarcinoma of the pancreas: A subset analysis from a randomized phase III trial (MPACT). Eur J Cancer. 2016 Jan; 52:85-91. Doi: 10.1016/j.ejca.2015.10.017. Epub 2015 Dec 1.
  • Wang-Gillam A, Li CP, Bodoky G, Dean A, Shan YS, Jameson G, Macarulla T, Lee KH, Cunningham D, Blanc JF, Hubner RA, Chiu CF, Schwartsmann G, Siveke JT, Braiteh F, Moyo V, Belanger B, Dhindsa N, Bayever E, Von Hoff DD, Chen LT; NAPOLI-1 Study Group. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. Lancet. 2016 Feb 6; 387(10018):545-57. Doi: 10.1016/S0140-6736(15)00986-1. Epub 2015 Nov 29. Erratum in:Lancet. 2016 Feb 6; 387(10018):536
  • Verdaguer H, Tabernero J, Macarulla T. Ramucirumab in metastatic colorectal cancer: evidence to date and place in therapy. Ther Adv Med Oncol 2016 May 8(3):230–42.
  • Scheithauer W, Ramanathan RK, Moore M, Macarulla T, Goldstein D, Hammel P, et al. Dose modification and efficacy of nab-paclitaxel plus gemcitabine vs. gemcitabine for patients with metastatic pancreatic cancer: phase III MPACT trial. J Gastrointest Oncol. 2016 Jun; 7(3):469-78. Doi: 10.21037/jgo.2016.01.03.
  • M. Hidalgo , R. Álvarez , J. Gallego , C. Guillén-Ponce , B. Laquente , T. Macarulla  A. Muñoz , M. Salgado , R. Vera , J . Adeva ,  I. Alés ,  S. Arévalo , J. Blázquez , A. Calsina ,  A. Carmona ,  E. de Madaria , R. Díaz ,  L. Díez  T. Fernández ,  B. G. de Paredes , M. E. Gallardo , I. González , O. Hernando ,  P. Jiménez , A. López , C. López ,  F. López-Ríos , E. Martín , J. Martínez , A. Martínez,  J. Montans , R. Pazo , J. C. Plaza , I. Peiró ,  J. J. Reina , A. Sanjuanbenito , R. Yaya , Alfredo Carrato. Consensus guidelines for diagnosis, treatment and follow-up of patients with pancreatic cancer in Spain. Clin. Transl. Oncol. 2017 19-6, pp.667-681.
  • Grasselli J , Elez E , Caratù G  , Matito J  , Santos C  , Macarulla T  , Vidal J , Garcia M  , Viéitez JM  , Paéz D  , Falcó E  , lopez lopez C  ,Aranda E  , Jones F  , Sikri V  , Nuciforo P  , Fasani R  , Tabernero J  , Montagut C  , Azuara D  , Dienstmann R  , Salazar R  , Vivancos A. Concordance of blood- and tumor-based detection of RAS mutations to guide anti-EGFR therapy in metastatic colorectal cancer. Ann Oncol.2017 Jun 1; 28 (6): 1294-1301. doi: 10.1093 / annonc / mdx112.
  • Saura C  , Roda D  , Roselló S  , Oliveira M  , Macarulla T  , Pérez-Fidalgo JA , Morales-Barrera R  , Sanchis-García JM  , Musib L  , Budha N  , Zhu J  , Nannini M  , Chan WY  , Sanabria Bohórquez SM  , Meng RD , Lin K , Yan Y , Patel P  , Baselga J  , Tabernero J  , Cervantes A . A First-in-Human Phase I Study of the ATP-Competitive AKT Inhibitor Ipatasertib Demonstrates Robust and Safe Targeting of AKT in Patients with Solid Tumors. Cancer Discov.7-1, pp.102-113.